This ETF aims to meet the demand for weight loss stock investments.
Tema ETFs has been capitalizing on the risk appetite for weight loss stocks.
The GLP-1, Obesity & Cardiometabolic ETF (HRTS) has experienced a 26% increase in value since its launch in November.
Maurits Pot, the founder and CEO of the firm, believes that the successful weight loss business is not solely dependent on hype.
""GLP-1 drugs could be used for weight loss and other diseases, as companies we track and invest in are exploring various approaches," Pot said on CNBC's "ETF Edge" on Monday."
Eli Lilly and Novo Nordisk are his top holdings, with Ozempic and Wegovy being their respective manufacturers. His investments have increased by 57% and 38% so far this year.
GLP-1s will not deter new patients, according to Plus. He predicts that their price tags will decrease significantly in the next two to three years.
Drug pricing could potentially decrease from $12,000 to $6,000 annually, resulting in $500 monthly, according to Pot. He emphasizes that insurance coverage can make treatments more affordable for patients.
Markets
You might also like
- Delinquencies are on the rise while a record number of consumers are making minimum credit card payments.
- U.S. economy state weighs on little changed treasury yields.
- European markets predicted to sustain positive growth.
- Trump hints at imposing a 10% tariff on China starting in February.
- David Einhorn believes we are currently in the "Fartcoin" phase of the market cycle.